Abstract
Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Current Pharmaceutical Design
Title:Antiepileptic Treatments in Developing Countries
Volume: 23 Issue: 37
Author(s): Jeremy Jost*, Athanase Millogo and Pierre-Marie Preux
Affiliation:
- INSERM, Univ. Limoges, CHU Limoges, UMR_S 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, F-87000 Limoges,France
Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Abstract: Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Export Options
About this article
Cite this article as:
Jost Jeremy *, Millogo Athanase and Preux Pierre-Marie, Antiepileptic Treatments in Developing Countries, Current Pharmaceutical Design 2017; 23 (37) . https://dx.doi.org/10.2174/1381612823666170809103202
DOI https://dx.doi.org/10.2174/1381612823666170809103202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia
Current Pharmaceutical Design Stopping Drug Therapy in Epilepsy
Current Pharmaceutical Design Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews PET Radiotracers for Molecular Imaging of Serotonin 5-HT<sub>1A</sub> Receptors
Current Medicinal Chemistry Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Letters in Drug Design & Discovery An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Current Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Aspects of the Stability and Bioavailability of Carbohydrates and Carbohydrate Derivatives
Mini-Reviews in Medicinal Chemistry Longitudinal Functional MRI of Motor and Cognitive Recovery Following Stroke: A Review
Current Medical Imaging Natural Products as Modulators of Spermatogenesis: The Search for a Male Contraceptive
Current Molecular Pharmacology Synthesis, Anticonvulsant and Neurotoxicity Evaluation of Some Newer N-(2-benzoylbenzofuran-3-yl)-3-(substituted)-propanamide Analogs
Central Nervous System Agents in Medicinal Chemistry